1 HER-2 Targeted Drugs for Breast Cancer Market Overview
1.1 Product Overview and Scope of HER-2 Targeted Drugs for Breast Cancer
1.2 Classification of HER-2 Targeted Drugs for Breast Cancer by Types
1.2.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue Comparison by Types (2020-2025)
1.2.2 Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Types in 2018
1.2.3 Trastuzumab
1.2.4 Pertuzumab
1.2.5 Lapatinib
1.2.6 Neratinib
1.2.7 Trastuzumab Emtansine
1.2.8 Pyrotinib
1.2.9 Other
1.3 Global HER-2 Targeted Drugs for Breast Cancer Market by Application
1.3.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size and Market Share Comparison by Applications (2015-2025)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Other
1.4 Global HER-2 Targeted Drugs for Breast Cancer Market by Regions
1.4.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size (Million USD) Comparison by Regions (2015-2025)
1.4.1 North America (USA, Canada and Mexico) HER-2 Targeted Drugs for Breast Cancer Status and Prospect (2015-2025)
1.4.2 Europe (Germany, France, UK, Russia and Italy) HER-2 Targeted Drugs for Breast Cancer Status and Prospect (2015-2025)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) HER-2 Targeted Drugs for Breast Cancer Status and Prospect (2015-2025)
1.4.4 South America (Brazil, Argentina, Colombia) HER-2 Targeted Drugs for Breast Cancer Status and Prospect (2015-2025)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) HER-2 Targeted Drugs for Breast Cancer Status and Prospect (2015-2025)
1.5 Global Market Size of HER-2 Targeted Drugs for Breast Cancer (2015-2025)
2 Manufacturers Profiles
2.1 Roche
2.1.1 Business Overview
2.1.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Roche HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
2.2 Chugai Pharmaceutical
2.2.1 Business Overview
2.2.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
2.3 GlaxoSmithKline
2.3.1 Business Overview
2.3.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
2.4 Novartis
2.4.1 Business Overview
2.4.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Novartis HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
2.5 Pfizer
2.5.1 Business Overview
2.5.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Pfizer HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
2.6 CANbridge
2.6.1 Business Overview
2.6.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 CANbridge HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
2.7 Puma Biotechnology
2.7.1 Business Overview
2.7.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
2.8 Hengrui Medicine
2.8.1 Business Overview
2.8.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
2.9 Beacon Pharmaceuticals Limited
2.9.1 Business Overview
2.9.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
2.10 Hetero Drugs
2.10.1 Business Overview
2.10.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2019)
3 Global HER-2 Targeted Drugs for Breast Cancer Market Competition, by Players
3.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue and Share by Players (2015-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 HER-2 Targeted Drugs for Breast Cancer Players Market Share
3.2.2 Top 10 HER-2 Targeted Drugs for Breast Cancer Players Market Share
3.3 Market Competition Trend
4 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Regions
4.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue and Market Share by Regions
4.2 North America HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
4.3 Europe HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
4.4 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
4.5 South America HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
4.6 Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
5 North America HER-2 Targeted Drugs for Breast Cancer Revenue by Countries
5.1 North America HER-2 Targeted Drugs for Breast Cancer Revenue by Countries (2015-2019)
5.2 USA HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
5.3 Canada HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
5.4 Mexico HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
6 Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Countries
6.1 Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Countries (2015-2019)
6.2 Germany HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
6.3 UK HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
6.4 France HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
6.5 Russia HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
6.6 Italy HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
7 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Countries
7.1 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Countries (2015-2019)
7.2 China HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
7.3 Japan HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
7.4 Korea HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
7.5 India HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
7.6 Southeast Asia HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
8 South America HER-2 Targeted Drugs for Breast Cancer Revenue by Countries
8.1 South America HER-2 Targeted Drugs for Breast Cancer Revenue by Countries (2015-2019)
8.2 Brazil HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
8.3 Argentina HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
8.4 Colombia HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
9 Middle East and Africa Revenue HER-2 Targeted Drugs for Breast Cancer by Countries
9.1 Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Countries (2015-2019)
9.2 Saudi Arabia HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
9.3 UAE HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
9.4 Egypt HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
9.5 Nigeria HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
9.6 South Africa HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2015-2019)
10 Global HER-2 Targeted Drugs for Breast Cancer Market Segment by Type
10.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue and Market Share by Type (2015-2019)
10.2 Global HER-2 Targeted Drugs for Breast Cancer Market Forecast by Type (2020-2025)
10.3 Trastuzumab Revenue Growth Rate (2015-2025)
10.4 Pertuzumab Revenue Growth Rate (2015-2025)
10.5 Lapatinib Revenue Growth Rate (2015-2025)
10.6 Neratinib Revenue Growth Rate (2015-2025)
10.7 Trastuzumab Emtansine Revenue Growth Rate (2015-2025)
10.8 Pyrotinib Revenue Growth Rate (2015-2025)
10.9 Other Revenue Growth Rate (2015-2025)
11 Global HER-2 Targeted Drugs for Breast Cancer Market Segment by Application
11.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Application (2015-2019)
11.2 HER-2 Targeted Drugs for Breast Cancer Market Forecast by Application (2020-2025)
11.3 Hospital Revenue Growth (2015-2019)
11.4 Clinic Revenue Growth (2015-2019)
11.5 Drug Center Revenue Growth (2015-2019)
11.6 Other Revenue Growth (2015-2019)
12 Global HER-2 Targeted Drugs for Breast Cancer Market Size Forecast (2020-2025)
12.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size Forecast (2020-2025)
12.2 Global HER-2 Targeted Drugs for Breast Cancer Market Forecast by Regions (2020-2025)
12.3 North America HER-2 Targeted Drugs for Breast Cancer Revenue Market Forecast (2020-2025)
12.4 Europe HER-2 Targeted Drugs for Breast Cancer Revenue Market Forecast (2020-2025)
12.5 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue Market Forecast (2020-2025)
12.6 South America HER-2 Targeted Drugs for Breast Cancer Revenue Market Forecast (2020-2025)
12.7 Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Revenue Market Forecast (2020-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
